Experimental Chemotherapy in a Transplantable Renal Adenocarcinoma
- 1 January 1983
- journal article
- research article
- Published by S. Karger AG in Urologia Internationalis
- Vol. 38 (3) , 162-165
- https://doi.org/10.1159/000280882
Abstract
Difluoromethylornithine (DFMO) and methylglyoxal bis (guanylhydrazone) (MGBG), inhibitors of ornithine decarboxylase (ODC) and S-adenosylmethionine decarboxylase (AMDC), respectively, were tested for antitumor activity in the BALB/c mouse renal adenocarcinoma model, in which ODC and AMDC activity are elevated compared to the normal kidney. An indirect effector of AMDC synthesis, arabinofuranosyladenine and an inhibitor of AMDC synthesis, cycloleucin (CL), were tested in this model. Simultaneous administration of both DFMO and MGBG affected the growth of renal adenocarcinoma less than did administration of DFMO or MGBG alone. Combinations of inhibitors of polyamine synthesis demonstrated a high toxicity with low therapeutic activity. The most effective tumor suppression was observed with CL alone, but associated toxicity was severe. Suramin, an ODC stimulator, may enhanced tumor growth.Keywords
This publication has 0 references indexed in Scilit: